- Alpha Cognition (ACOG) has launched a marketed public offering of units for gross proceeds of up to $10 million
- Pricing and size of the offering have yet to be decided
- The company will grant the agents an over-allotment option
- The company intends to use the proceeds to develop and market its flagship formulations against Alzheimer’s and ALS
- Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases
- Alpha Cognition Inc. (ACOG) is down 8.16 per cent on the day, trading at C$0.45 per share at 2:30 pm ET
Alpha Cognition (ACOG) has launched a marketed public offering of units for gross proceeds of up to $10 million.
The pricing, terms and size of the offering will be determined in the context of the market.
The offering will be conducted on the terms and conditions of an agency agreement to be entered into between the company and Raymond James Ltd. as sole bookrunner and lead agent on behalf of a syndicate of agents.
The company will grant the agents an option to sell up to an additional 15 per cent of the units sold under the offering. The over-allotment option may be exercised in whole or in part at any time up to 30 days following the closing date of the offering.
The company intends to use the proceeds for working capital, general corporate purposes and for the marketing and clinical development of its flagship formulations:
- Alpha-1062, which is intended as a treatment for Alzheimer’s Disease
- Alpha-0602, which is intended as a treatment for ALS
The offering is expected to close on or about November 25, 2022.
Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases.
Alpha Cognition Inc. (ACOG) is down 8.16 per cent on the day, trading at C$0.45 per share at 2:30 pm ET.